Análise do efeito da duloxetina no crescimento de tumor de Ehrlich em camundongos. Estudo randomizado, encoberto
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Tipo de documento: | Tese |
Idioma: | por |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=5036396 http://repositorio.unifesp.br/handle/11600/50352 |
Resumo: | Background and Objectives: Adjuvants may promote analgesic effect and reduce the amount of opioids required in the treatment of cancer pain. The aim of the study was to analyze whether duloxetine, used in the treatment of cancer pain, has a direct influence on growth of the Ehrlich tumor inoculated in mice. Method: A total of 40 mice were divided into 4 groups, and 5 of each group were evaluated for survival. Mice received 5 (D5 group), 10 (D10), 30 mg / kg (D30) duloxetine or saline solution (C). The following were evaluated: survival; volume of ascites; abdominal circumference; living tumor cells in the ascites; hemogram; leukocytes in the ascites, lymph nodes, bone marrow; cytokines (interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukins (IL) 6, 10, 17; monocyte chemotactic protein, (MCP); nitrite and nitric oxide (NO) in ascites and spleen; arginase, superoxide dismutase (SOD) in ascites, immunophenotyping of the spleen. Results: There was no difference in survival, weight, abdominal circumference, ascites volume, and number of tumor cells in ascites. There was no difference in leukocytes in the spleen. The number of leukocytes in mesenteric lymph node was higher with duloxetine; in the bone marrow was higher with 10 and 30 mg / kg. The number of GV was lower in D5 and D10 and hemoglonia was lower in D5; GB did not change with duloxetine; the platelet count was lower with duloxetine 10 and 30mg / kg. TNF-α in ascites was lower with 10mg / kg; serum IFN-γ was lower at 30mg / kg; IL6 in the spleen was lower at 5mg / kg; and IL17 in the spleen was greater at 30mg / kg. NO in the spleen was higher with 30mg / kg; in the ascites was lower with 10mg / kg. SOD in ascites was higher with 5 and 10 mg / kg. Antibody for CD3 was lower at 5 and 10mg / kg; for CD4 was lower with 5 and 30mg / kg; for CD8 was lower with 5mg / kg; or CD28 was lower with 5 and 30mg / kg. Conclusions: Duloxetine may play a role in tumor growth, as evidenced by anemia, by the reduction of CD4 + T cells, CD8 + T cells and their activation in the spleen, and by the pattern of cytokines that characterize an M2 macrophage pattern. |
id |
UFSP_82c677201059e30aaf568722a69a0e2a |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/50352 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Análise do efeito da duloxetina no crescimento de tumor de Ehrlich em camundongos. Estudo randomizado, encobertoAnalysis of the effect of duloxetine in Ehrlich tumor growth in mice. Randomised, blind studyDuloxetineTumor growthCancerDuloxetinaCrescimento tumoralCâncerBackground and Objectives: Adjuvants may promote analgesic effect and reduce the amount of opioids required in the treatment of cancer pain. The aim of the study was to analyze whether duloxetine, used in the treatment of cancer pain, has a direct influence on growth of the Ehrlich tumor inoculated in mice. Method: A total of 40 mice were divided into 4 groups, and 5 of each group were evaluated for survival. Mice received 5 (D5 group), 10 (D10), 30 mg / kg (D30) duloxetine or saline solution (C). The following were evaluated: survival; volume of ascites; abdominal circumference; living tumor cells in the ascites; hemogram; leukocytes in the ascites, lymph nodes, bone marrow; cytokines (interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukins (IL) 6, 10, 17; monocyte chemotactic protein, (MCP); nitrite and nitric oxide (NO) in ascites and spleen; arginase, superoxide dismutase (SOD) in ascites, immunophenotyping of the spleen. Results: There was no difference in survival, weight, abdominal circumference, ascites volume, and number of tumor cells in ascites. There was no difference in leukocytes in the spleen. The number of leukocytes in mesenteric lymph node was higher with duloxetine; in the bone marrow was higher with 10 and 30 mg / kg. The number of GV was lower in D5 and D10 and hemoglonia was lower in D5; GB did not change with duloxetine; the platelet count was lower with duloxetine 10 and 30mg / kg. TNF-α in ascites was lower with 10mg / kg; serum IFN-γ was lower at 30mg / kg; IL6 in the spleen was lower at 5mg / kg; and IL17 in the spleen was greater at 30mg / kg. NO in the spleen was higher with 30mg / kg; in the ascites was lower with 10mg / kg. SOD in ascites was higher with 5 and 10 mg / kg. Antibody for CD3 was lower at 5 and 10mg / kg; for CD4 was lower with 5 and 30mg / kg; for CD8 was lower with 5mg / kg; or CD28 was lower with 5 and 30mg / kg. Conclusions: Duloxetine may play a role in tumor growth, as evidenced by anemia, by the reduction of CD4 + T cells, CD8 + T cells and their activation in the spleen, and by the pattern of cytokines that characterize an M2 macrophage pattern.Justificativa e Objetivos: Os adjuvantes podem promover efeito analgésico e reduzir a quantidade de opioides necessários no tratamento da dor oncológica. O estudo teve como objetivo analisar se a duloxetina, usada no tratamento da dor do câncer, tem influência direta no direta no crescimento do tumor de Ehrlich inoculado em camundongos. Métodos: Foram utilizados 40 camundongos divididos em 4 grupos, sendo que 5 de cada grupo foram avaliados quanto a sobrevida. Os camundongos receberam 5 (grupo D5), 10 (D10), 30 mg/Kg (D30) de duloxetina ou solução salina (C). Foram avaliados: sobrevida; volume de ascite; circunferência abdominal; células tumorais vivas na ascite; hemograma; leucócitos na ascite, linfonodos, medula óssea; citocinas (interferon gama (IFN-γ), fator de necrose tumoral alfa (TNF-α), interleucinas (IL) 6, 10, 17; proteína quimiotática de monócito, MCP); nitrito e óxido nítrico (NO) na ascite e no baço; arginase, superóxido dismutase (SOD) na ascite, imunofenotipagem do baço. Resultados: Não houve diferença na sobrevida, peso, circunferência abdominal, volume de ascite, e número de células tumorais na ascite. Não houve diferença nos leucócitos do baço. O número de leucócitos em linfonodo mesentérico foi maior com duloxetina; na medula óssea foi maior com 10 e 30 mg/Kg. O número de GV foi menor em D5 e D10 e a hemoglonia foi menor em D5; GB não alteraram com duloxetina; a plaquetose foi menor com duloxetina 10 e 30mg/Kg. O TNF-α na ascite foi menor com 10mg/Kg; o IFN-γ no soro foi menor com 30mg/Kg; a IL6 no baço foi menor com 5mg/Kg; e a IL17 no baço foi maior com 30mg/Kg. O NO no baço foi maior com 30mg/Kg; na ascite foi menor com 10mg/Kg. A SOD na ascite foi maior com 5 e 10 mg/Kg. O anticorpo para CD3 foi menor com 5 e 10mg/kg; para CD4 foi menor com 5 e 30mg/kg; para CD8 foi menor com 5mg/Kg; para CD 28 foi menor com 5 e 30mg/kg. Conclusões: A duloxetina pode ter papel no crescimento tumoral, evidenciado através da anemia, pela diminuição de linfócitos T CD4+, T CD8+ e de sua ativação no baço, e pelo padrão de citocinas que caracterizam um padrão macrófago M2.Dados abertos - Sucupira - Teses e dissertações (2017)Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Universidade Federal de São Paulo (UNIFESP)Sakata, Rioko Kimiko [UNIFESP]Nascimento, Flávia Raquel Fernandes dohttp://lattes.cnpq.br/9073277157401960http://lattes.cnpq.br/9796401471904195http://lattes.cnpq.br/1952516967110832Universidade Federal de São Paulo (UNIFESP)Moura, Ed Carlos Rey [UNIFESP]2019-06-19T14:57:47Z2019-06-19T14:57:47Z2017info:eu-repo/semantics/doctoralThesisinfo:eu-repo/semantics/publishedVersion79 f.application/pdfhttps://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=5036396http://repositorio.unifesp.br/handle/11600/50352porinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-10T12:31:48Zoai:repositorio.unifesp.br/:11600/50352Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-10T12:31:48Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Análise do efeito da duloxetina no crescimento de tumor de Ehrlich em camundongos. Estudo randomizado, encoberto Analysis of the effect of duloxetine in Ehrlich tumor growth in mice. Randomised, blind study |
title |
Análise do efeito da duloxetina no crescimento de tumor de Ehrlich em camundongos. Estudo randomizado, encoberto |
spellingShingle |
Análise do efeito da duloxetina no crescimento de tumor de Ehrlich em camundongos. Estudo randomizado, encoberto Moura, Ed Carlos Rey [UNIFESP] Duloxetine Tumor growth Cancer Duloxetina Crescimento tumoral Câncer |
title_short |
Análise do efeito da duloxetina no crescimento de tumor de Ehrlich em camundongos. Estudo randomizado, encoberto |
title_full |
Análise do efeito da duloxetina no crescimento de tumor de Ehrlich em camundongos. Estudo randomizado, encoberto |
title_fullStr |
Análise do efeito da duloxetina no crescimento de tumor de Ehrlich em camundongos. Estudo randomizado, encoberto |
title_full_unstemmed |
Análise do efeito da duloxetina no crescimento de tumor de Ehrlich em camundongos. Estudo randomizado, encoberto |
title_sort |
Análise do efeito da duloxetina no crescimento de tumor de Ehrlich em camundongos. Estudo randomizado, encoberto |
author |
Moura, Ed Carlos Rey [UNIFESP] |
author_facet |
Moura, Ed Carlos Rey [UNIFESP] |
author_role |
author |
dc.contributor.none.fl_str_mv |
Sakata, Rioko Kimiko [UNIFESP] Nascimento, Flávia Raquel Fernandes do http://lattes.cnpq.br/9073277157401960 http://lattes.cnpq.br/9796401471904195 http://lattes.cnpq.br/1952516967110832 Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Moura, Ed Carlos Rey [UNIFESP] |
dc.subject.por.fl_str_mv |
Duloxetine Tumor growth Cancer Duloxetina Crescimento tumoral Câncer |
topic |
Duloxetine Tumor growth Cancer Duloxetina Crescimento tumoral Câncer |
description |
Background and Objectives: Adjuvants may promote analgesic effect and reduce the amount of opioids required in the treatment of cancer pain. The aim of the study was to analyze whether duloxetine, used in the treatment of cancer pain, has a direct influence on growth of the Ehrlich tumor inoculated in mice. Method: A total of 40 mice were divided into 4 groups, and 5 of each group were evaluated for survival. Mice received 5 (D5 group), 10 (D10), 30 mg / kg (D30) duloxetine or saline solution (C). The following were evaluated: survival; volume of ascites; abdominal circumference; living tumor cells in the ascites; hemogram; leukocytes in the ascites, lymph nodes, bone marrow; cytokines (interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukins (IL) 6, 10, 17; monocyte chemotactic protein, (MCP); nitrite and nitric oxide (NO) in ascites and spleen; arginase, superoxide dismutase (SOD) in ascites, immunophenotyping of the spleen. Results: There was no difference in survival, weight, abdominal circumference, ascites volume, and number of tumor cells in ascites. There was no difference in leukocytes in the spleen. The number of leukocytes in mesenteric lymph node was higher with duloxetine; in the bone marrow was higher with 10 and 30 mg / kg. The number of GV was lower in D5 and D10 and hemoglonia was lower in D5; GB did not change with duloxetine; the platelet count was lower with duloxetine 10 and 30mg / kg. TNF-α in ascites was lower with 10mg / kg; serum IFN-γ was lower at 30mg / kg; IL6 in the spleen was lower at 5mg / kg; and IL17 in the spleen was greater at 30mg / kg. NO in the spleen was higher with 30mg / kg; in the ascites was lower with 10mg / kg. SOD in ascites was higher with 5 and 10 mg / kg. Antibody for CD3 was lower at 5 and 10mg / kg; for CD4 was lower with 5 and 30mg / kg; for CD8 was lower with 5mg / kg; or CD28 was lower with 5 and 30mg / kg. Conclusions: Duloxetine may play a role in tumor growth, as evidenced by anemia, by the reduction of CD4 + T cells, CD8 + T cells and their activation in the spleen, and by the pattern of cytokines that characterize an M2 macrophage pattern. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017 2019-06-19T14:57:47Z 2019-06-19T14:57:47Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/doctoralThesis |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
doctoralThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=5036396 http://repositorio.unifesp.br/handle/11600/50352 |
url |
https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=5036396 http://repositorio.unifesp.br/handle/11600/50352 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
79 f. application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
publisher.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268316979560448 |